What is PredictImmune?
Founded in 2017 and headquartered in Cambridge, England, PredictImmune is at the forefront of developing prognostic tests designed to address immune-mediated diseases. This enterprise-level funding underscores the company's critical role in advancing diagnostic capabilities within the healthcare sector. The company's focus on prognostic testing suggests a strategic approach to patient care, aiming to predict disease progression and inform treatment strategies for complex conditions.
How much funding has PredictImmune raised?
PredictImmune has raised a total of $16.6M across 2 funding rounds:
Series A
$5.9M
Series B
$10.7M
Series A (2018): $5.9M with participation from The Wellcome Trust
Series B (2019): $10.7M led by BFG and Parkwalk
Key Investors in PredictImmune
Parkwalk
Parkwalk is a leading investor in university spinouts, focusing on deeptech innovations emerging from the UK's top universities. They provide funding, expertise, and networks to help these companies thrive across sectors like AI, Quantum Computing, and HealthTech.
The Wellcome Trust
Wellcome is an independent global charitable foundation that supports discovery research and tackles urgent health challenges. They fund science, policy, and public engagement to improve health through grants, partnerships, and advocacy.
BFG
Undisclosed investor participating in the funding round.
What's next for PredictImmune?
The recent major strategic investment signals a pivotal growth phase for PredictImmune. This capital infusion is expected to accelerate the company's research and development efforts, potentially expanding its test portfolio and market reach. Further expansion into new therapeutic areas or geographical markets is anticipated, leveraging the company's established expertise in immune-mediated diseases. The company's trajectory suggests a strong potential for future breakthroughs and market leadership in the diagnostic testing landscape.
See full PredictImmune company page
